Company Overview of Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. operates as a biotechnology company. It offers OmniRat, an antibody platform that generates human monoclonal antibodies based on transgenic rats. Open Monoclonal Technology, Inc. has a strategic alliance with Crystal Bioscience, Inc. The company was founded in 2007 and is based in Palo Alto, California. As of January 8, 2016, Open Monoclonal Technology, Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
2747 Ross Road
Palo Alto, CA 94303
Founded in 2007
Key Executives for Open Monoclonal Technology, Inc.
Founder, Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.
Open Monoclonal Technology, Inc. Key Developments
Ligand Pharmaceuticals Incorporated, Open Monoclonal Technology, Inc. - M&A Call
Dec 17 15
To discuss the signing of agreements for Ligand to acquire OMT, Inc
Open Monoclonal Technology, Inc. Announces OmniAb(TM) License to Seattle Genetics
Nov 2 15
Open Monoclonal Technology, Inc. announced license that provides Seattle Genetics, Inc. with access to OMT's proprietary OmniRat(R), OmniMouse(R) and OmniFlic(TM) human antibody generation platforms. Seattle Genetics becomes OMT's nineteenth partner globally.
ARMO BioSciences, Inc. and Open Monoclonal Technology, Inc. Announce Licensing Agreement
Oct 16 15
ARMO BioSciences, Inc. (ARMO) and Open Monoclonal Technology, Inc. (OMT) announced a licensing agreement providing ARMO with exclusive rights to OMT’s Programmed Cell Death Protein 1 (PD-1) assets as well as unlimited access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic human antibody generation platforms. The addition of an anti-PD-1 program to ARMO's pipeline of cytokine immunotherapies reinforces the company's commitment to the development of safe and effective treatments for cancer. ARMO's clinical stage PEGylated form of recombinant human IL-10, known as AM0010, and anti-PD-1 antibodies work through complementary but distinct mechanisms on CD8+ T cells so the combination maximizes the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells, which are considered to be central to clinical response. In ongoing clinical studies, AM0010 has already shown activity as a monotherapy and in combination with anti-PD-1 agents in immune-sensitive tumors such as melanoma, RCC, NSCLC and others not previously thought to be sensitive to immunotherapy such as colorectal and pancreatic cancers. Early results from these trials are suggestive of AM0010's role in augmenting activated tumor infiltrating T cells and PD-1 expression, thereby bestowing anti-PD-1 sensitivity on tumors, including those that had been refractory to anti-PD-1 treatment.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 17, 2015